NCT03850379

Ciprofloxacin Versus Levofloxacin in Stem Cell Transplant

Ciprofloxacin Versus Levofloxacin and Rate of Breakthrough Infections in Hematopoietic Stem Cell Transplant Patients

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 308 (actual)
• Sponsor: Henry Ford Health System · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

Ciprofloxacin and levofloxacin are both in guidelines to use for prophylaxis in autologous and allogeneic Stem cell transplant.Ciprofloxacin was recently replaced by levofloxacin as the preferred agent in some transplant centers. In some small retrospective studies ciprofloxacin prophylaxis was associated with a higher rate of breakthrough gram positive bloodstream infections. However, the optimum oral agent for antibacterial prophylaxis in transplant recipients remains uncertain.

Conditions

• Prophylaxis
• Stem Cell Transplant Complications

Interventions

Type	Name	Description
DRUG	Levofloxacin	This is a prospective study comparing consecutive patients who will be be receiving ciprofloxacin prophylaxis vs. levofloxacin prophylaxis for Stem cell transplant till engraftment defined as ANC \>1000
DRUG	Ciprofloxacin	This is a prospective study comparing consecutive patients who will be be receiving ciprofloxacin prophylaxis vs. levofloxacin prophylaxis for Stem cell transplant till engraftment defined as ANC \>1000

Timeline

• Start date: 2018-03-14
• Primary completion: 2024-08-30
• Completion: 2024-08-30
• First posted: 2019-02-21
• Last updated: 2025-10-20
• Results posted: 2025-10-20

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study